Eli Lilly to sign $2 billion AI drug discovery deal
Eli Lilly is reportedly signing a $2 billion agreement with Hong Kong-based Insilico Medicine. The deal grants Lilly rights to sell a new GLP-1 diabetes drug.
Xurve View
洞察:
Xurve View
Eli Lilly and Company is reportedly nearing a $2 billion agreement with Insilico Medicine, a biotechnology firm specializing in the use of artificial intelligence for pharmaceutical discovery. According to a report from the Financial Times, the deal underscores a significant investment in AI-driven healthcare solutions.
